Sustained and clinically meaningful improvements in both day and night time aspects of HRQoL are observed with abatacept treatment in patients with rheumatoid arthritis and previous inadequate response to MTX: 5-year data from the AIM trial

Category Primary study
ConferenceAmerican College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting; Atlanta, Georgia; 2010. Published in: Arthritis & Rheumatism
Year 2010
Loading references information
This article has no abstract
Epistemonikos ID: 4aa400f5ad33eb71aa1eab5fa2d583e9a77157c3
First added on: Oct 16, 2017